{"id":2957,"date":"2026-09-08T07:30:00","date_gmt":"2026-09-08T11:30:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2957"},"modified":"2026-09-08T20:40:19","modified_gmt":"2026-09-09T00:40:19","slug":"inbrx-106-adds-a-randomized-response-signal-in-hnscc","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2957","title":{"rendered":"INBRX-106 Adds a Randomized Response Signal in HNSCC"},"content":{"rendered":"

Evidence<\/strong> Source-gap catch-up · Published<\/strong> September 8, 2026 · Discovery<\/strong> September 8, 2026 · Importance<\/strong> 4\/5 · Direction<\/strong> Positive<\/p>\n

\"INBRX-106<\/p>\n

Summary<\/h4>\n

Inhibrx reported primary-endpoint results from the randomized Phase II portion of HexAgon in first-line, treatment-naive, PD-L1 CPS at least 20 metastatic or unresectable recurrent head and neck squamous-cell carcinoma. INBRX-106 plus pembrolizumab produced a confirmed objective-response rate of 48.3% versus 26.5% with pembrolizumab alone among 63 evaluable patients. Four complete responses occurred with the combination and none with control. Interim median progression-free survival was 9.6 versus 4.9 months. These controlled data are directionally positive for OX40 agonism, but the small analysis lacks confidence intervals, hazard ratios, prespecified statistical detail, mature durability and comprehensive safety reporting.<\/p>\n

What Happened<\/h4>\n

The Phase II cohort randomized 68 patients across more than 80 sites in the United States, Europe and Asia; 29 combination and 34 control patients were evaluable at the August 19 cutoff. Six-month progression-free-survival rates were 72.4% and 42.8%, respectively. In the exploratory HPV-positive subsets, comprising only 10 and nine evaluable patients, confirmed response was 80.0% versus 33.3%, complete response was 30.0% versus zero, and six-month progression-free survival was 90.0% versus 33.0%.<\/p>\n

Inhibrx described the combination as generally manageable, with rash, fatigue and diarrhea the most common treatment-related adverse events and predominantly low grade. Counts by grade, immune-mediated toxicity, exposure-adjusted incidence, treatment discontinuation and fatal events were not provided. The company plans an approximately 50-patient HPV-positive oropharyngeal expansion and intends to seek FDA alignment on a possible accelerated pathway; no FDA agreement or approval framework has been disclosed.<\/p>\n

Deep Analysis<\/h4>\n

OX40 costimulation adds activity:<\/strong> The randomized control, absolute response difference, emergence of complete responses and consistent early progression-free-survival separation support pharmacologic contribution beyond pembrolizumab alone. The earlier pharmacodynamic observation of peripheral CD4- and CD8-positive T-cell proliferation is mechanistically coherent with OX40 clustering. Counterevidence is the limited evaluable population, immature survival data and absence of inferential statistics.<\/p>\n

Enrichment and chance magnify the signal:<\/strong> PD-L1 CPS enrichment and a small HPV-positive subgroup could select patients with immunologically responsive disease, while unreported covariate imbalances or assessment timing may contribute. The control response rate is broadly plausible, but this does not eliminate chance, post-randomization evaluability effects or open-label bias in investigator-assessed endpoints. Similar directional effects across response depth and progression-free survival argue against dismissing the result as a single noisy endpoint.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: randomized controlled Phase II cohort; 68 randomized and 63 evaluable; confirmed response, complete-response and interim progression-free-survival differences; same-day company disclosure. Company claims: first OX40 agonist to show randomized clinical benefit and a potential accelerated pathway. Missing facts: protocol-defined analysis plan, central review, confidence intervals, hazard ratio, p-values, censoring, multiplicity, response duration, overall survival and full adverse-event tables. Upgrade evidence would be centrally reviewed durability, statistically robust PFS and reproducible HPV-positive activity in the expansion.<\/p>\n

Company and Product Background<\/h4>\n

Inhibrx Biosciences is a clinical-stage biotechnology company created through the 2024 separation of assets that were not acquired by Sanofi. INBRX-106 is a hexavalent single-domain-antibody agonist of OX40, also called CD134, a costimulatory receptor expressed on activated T cells. High-order receptor clustering is intended to enhance T-cell activation, survival and antigen-driven expansion while pembrolizumab removes PD-1-mediated inhibitory signaling.<\/p>\n

Head and neck squamous-cell carcinoma includes biologically heterogeneous HPV-positive and HPV-negative disease. Pembrolizumab is established first-line therapy in PD-L1-selected recurrent or metastatic disease, making incremental response depth and durable disease control clinically relevant. OX40 activation can also expand regulatory or effector populations depending on context, and chronic stimulation may not translate into durable antitumor immunity; target engagement alone therefore does not establish benefit.<\/p>\n

InSilens Take<\/h4>\n

This is a meaningful rescue signal for a target class that has repeatedly struggled to translate agonist biology into clinical benefit. The controlled comparison is more informative than a conventional single-arm immuno-oncology readout, and the complete responses merit follow-up. It is not yet registrational evidence, and the HPV-positive result is too small to define a biomarker strategy. The next value-inflecting evidence is durable, independently reviewed response and PFS in a larger cohort with a complete immune-toxicity profile and documented regulatory alignment.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n4 \/ 5 — a randomized efficacy signal in first-line HNSCC materially advances a historically difficult immune-costimulatory target<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nPositive — multiple controlled efficacy measures favor the combination, limited by small size and incomplete reporting<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — patient counts, endpoint values, cutoff and development plans disclosed on the company’s canonical release, linked to the registered study<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate — randomization improves attribution, but statistical precision, independent review and complete safety data are missing<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Inhibrx reported primary-endpoint results from the randomized Phase II portion of HexAgon in first-line, treatment-naive, PD-L1 CPS at least 20 metastatic or unresectable recurrent head and neck squamous-cell carcinoma. INBRX-106 plus pembrolizumab produced a…<\/p>\n","protected":false},"author":1,"featured_media":2977,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[234,606,105,607,522],"class_list":["post-2957","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-head-and-neck-squamous-cell-carcinoma","tag-inbrx-106","tag-inhibrx-biosciences","tag-ox40","tag-pembrolizumab"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2957"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2957\/revisions"}],"predecessor-version":[{"id":2990,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2957\/revisions\/2990"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2977"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}